Literature DB >> 21412945

A novel nonsense mutation in the APTX gene associated with delayed DNA single-strand break removal fails to enhance sensitivity to different genotoxic agents.

Claudia Crimella1, Orazio Cantoni, Andrea Guidarelli, Chiara Vantaggiato, Andrea Martinuzzi, Mara Fiorani, Catia Azzolini, Genny Orso, Nereo Bresolin, Maria Teresa Bassi.   

Abstract

APTX is the gene involved in ataxia with oculomotor apraxia type 1 (AOA1), a recessive disorder with early-onset cerebellar ataxia, oculomotor apraxia and peripheral neuropathy. The encoded protein, aprataxin, is a DNA repair protein processing the products of abortive ligations, 5'-adenylated DNA. We describe a novel nonsense mutation in APTX, c.892C>T (p.Gln298X), segregating in two AOA1 patients and leading to the loss of aprataxin protein in patient's cells. These cells, while exhibiting reduced catalase activity, are not hypersensitive to toxicity elicited by H(2)O(2) exposure at either physiologic or ice-bath temperature. On the other hand, the rate of repair of DNA single-strand-breaks (SSBs) induced in both conditions is always significantly slower in AOA1 cells. By using the alkylating agent methyl methane sulphonate (MMS) we confirmed the association of the APTX mutation with a DNA repair defect in the absence of detectable changes in susceptibility to toxicity. These results, while consistent with a role of aprataxin in the repair of SSBs induced by H(2)O(2), or MMS, demonstrate that other mechanisms may be recruited in AOA1 cells to complete the repair process, although at a slower rate. Lack of hypersensitivity to the oxidant, or MMS, also implies that delayed repair is not per se a lethal event.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412945     DOI: 10.1002/humu.21464

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

Review 1.  Neurological disorders associated with DNA strand-break processing enzymes.

Authors:  Bingcheng Jiang; J N Mark Glover; Michael Weinfeld
Journal:  Mech Ageing Dev       Date:  2016-07-25       Impact factor: 5.432

2.  Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.

Authors:  Mathilde Renaud; Maria-Céu Moreira; Bondo Ben Monga; Diana Rodriguez; Rabab Debs; Perrine Charles; Malika Chaouch; Farida Ferrat; Chloé Laurencin; Laurent Vercueil; Martial Mallaret; Abderrahim M'Zahem; Lamia Ali Pacha; Meriem Tazir; Caroline Tilikete; Elisabeth Ollagnon; François Ochsner; Thierry Kuntzer; Hans H Jung; Jean-Marie Beis; Jean-Claude Netter; Atbin Djamshidian; Mattew Bower; Armand Bottani; Richard Walsh; Sinead Murphy; Thomas Reiley; Éric Bieth; Filip Roelens; Bwee Tien Poll-The; Charles Marques Lourenço; Laura Bannach Jardim; Rachel Straussberg; Pierre Landrieu; Emmanuel Roze; Stéphane Thobois; Jean Pouget; Claire Guissart; Cyril Goizet; Alexandra Dürr; Christine Tranchant; Michel Koenig; Mathieu Anheim
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

3.  Progressive ataxia associated with ocular apraxia type 1 (AOA1) with a presence of a novel mutation on the aprataxin gene.

Authors:  Abdul Qayyum Rana; Osama A Khan; Raza Akthar
Journal:  Ann Indian Acad Neurol       Date:  2013-04       Impact factor: 1.383

4.  Naringenin Ameliorates Drosophila ReepA Hereditary Spastic Paraplegia-Linked Phenotypes.

Authors:  Barbara Napoli; Sentiljana Gumeni; Alessia Forgiarini; Marianna Fantin; Concetta De Filippis; Elena Panzeri; Chiara Vantaggiato; Genny Orso
Journal:  Front Neurosci       Date:  2019-11-19       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.